A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy.
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2011
At a glance
- Drugs Valsartan/hydrochlorothiazide (Primary) ; Hydrochlorothiazide
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms VAL-DICTATE
- Sponsors Novartis
- 01 Jun 2011 Actual end date (Nov 2005) added as rported by ClinicalTrials.gov.
- 21 Mar 2008 Status change from in progress to completed, as reported by clinicaltrials.gov.
- 30 Nov 2005 New trial record.